• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Vascular Endothelial Growth Factor (VEGF) Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 - Product Image

Vascular Endothelial Growth Factor (VEGF) Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013

  • Published: February 2013
  • Region: Global
  • 97 Pages
  • BioPharm Reports (VennBio Ltd.)

Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is targeted using antibodies and tyrosine kinase inhibitors, and antiangiogenic therapy is a standard treatment for many cancers, including colorectal and non-small cell lung cancer.

While VEGF inhibitors such as bevacizumab (Avastin®) provide valuable treatment options, these benefits are not seen in all patients and cancer types. Today, there is an urgent need for predictive biomarkers to enable those patients most likely to benefit from VEGF inhibition, to be identified. This report provides a review of findings to date on biomarkers associated with the use bevacizumab (Avastin®); both therapy-indicating and prognostic.

The identification of therapy-indicating and prognostic biomarkers relating to antiangiogenic therapy is in its early stages, however important advances have been made. This report identifies the latest findings on ten different cancers and includes an evaluation of candidate biomarkers as a basis for interpreting patient outcomes according to RECIST criteria, and evaluates READ MORE >

Executive Summary

Chapter 1: Background

1.1 VEGF Inhibition
1.2 Bevacizumab
1.3 Biomarkers
1.4 This Report

Chapter 2 Colorectal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies

Summary
2.1 Introduction
2.2 Glycoprotein
2.3 Protein
2.4 Protein
2.5 Cells
2.6 Genetic
2.7 Physical
2.8 Genetic
2.9 Protein
2.10 Proteins
2.11 Proteins and Genetic
2.12 Image
2.13 Proteins
2.14 Protein

Chapter 3 Breast Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies

Summary
3.1 Introduction
3.2 Protein
3.3 Protein
3.4 Protein
3.5 Protein
3.6 Protein
3.7 Genetic
3.8 Protein

Chapter 4 Renal Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies

Summary
4.1 Introduction
4.2 Image
4.3 Protein
4.4 Physical
4.5 Protein
4.6 Body Characteristic

Chapter 5 Ovarian Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies

Summary
5.1 Introduction
5.2 Proteins
5.3 Proteins
5.4 Proteins
5.5 Proteins

Chapter 6 Lung Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies

Summary
6.1 Introduction
6.2 Physical Parameter
6.3 Protein
6.4 Genetic
6.5 Protein

Chapter 7 Liver Cancer: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies

Summary
7.1 Introduction
7.2 Protein
7.3 Image

Chapter 8 Other Cancers: Candidate Biomarkers identified in Patients receiving Bevacizumab-containing Therapies

Summary
8.1 Introduction
8.2 Proteins
8.3 Proteins
8.4 Protein
8.5 Protein
8.6 Physical
8.7 Physical
8.8 Physical

Chapter 9: Discussion

9.1 Overview
9.2 Colorectal Cancer
9.3 Breast Cancer:
9.4 Renal Cancer:
9.5 Ovarian Cancer
9.6 Lung Cancer
9.7 Liver Cancer
9.8 Other Cancers
9.9 Conclusions

Tables

Table 2.1 Candidates biomarkers identified in colorectal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 3.1 Candidates biomarkers identified in breast cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 4.1 Candidates biomarkers identified in renal cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 5.1 Candidates biomarkers identified in ovarian cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 6.1 Candidates biomarkers identified in lung cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 7.1 Candidates biomarkers identified in liver cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 8.1 Candidates biomarkers identified in other cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.1 Protein candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.2 Genetic candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.3 Image-based candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.4 Other candidate biomarkers identified in cancer patients receiving bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)

Figures

Figure 9.1 Candidate biomarkers types identified in cancer patients receiving bevacizumab-containing therapies
Figure 9.2 Cancer types evaluated for biomarkers identified in cancer patients receiving bevacizumab-containing therapies
Figure 9.3 Author countries (identified in this report) of cancers evaluated for biomarkers identified in cancer patients receiving bevacizumab-containing therapies

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos